Screening for cancer: lessons learned from the prostate, lung, colorectal, and ovarian cancer screening trial.

[1]  G. Andriole,et al.  Physical Activity and Benign Prostatic Hyperplasia-Related Outcomes and Nocturia , 2015, Medicine and science in sports and exercise.

[2]  Mark P Purdue,et al.  Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. , 2012, The New England journal of medicine.

[3]  J. Gohagan,et al.  Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. , 2012, Journal of the National Cancer Institute.

[4]  M. Roizen.  Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening , 2012 .

[5]  C. Gatsonis,et al.  Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening , 2012 .

[6]  J. Gohagan,et al.  Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. , 2011, JAMA.

[7]  David Chia,et al.  Mortality results from a randomized prostate-cancer screening trial. , 2009, The New England journal of medicine.

[8]  W. Willett,et al.  Multiple loci identified in a genome-wide association study of prostate cancer , 2008, Nature Genetics.

[9]  J. Gohagan,et al.  Prostate specific antigen changes as related to the initial prostate specific antigen: data from the prostate, lung, colorectal and ovarian cancer screening trial. , 2006, The Journal of urology.

[10]  R. Hayes,et al.  Supplemental and dietary vitamin E, beta-carotene, and vitamin C intakes and prostate cancer risk. , 2006, Journal of the National Cancer Institute.

[11]  Bernard Maitre,et al.  Screening by Chest Radiograph and Lung Cancer Mortality : The Prostate , Lung , Colorectal , and Ovarian ( PLCO ) Randomized Trial , 2022 .